The Rebate End-Run: Trump's Drug EO May Be a $750 Spread Story, Not a European Price Story

On 16 June 2026, the Nasdaq Biotechnology Index closed roughly 4% higher. That is the headline nobody expected. A week of commentary had braced the sector for a bloodbath once President Donald Trump signed his Most Favored Nation executive order on drug prices — the directive that would, in theory, tie American prescription prices to the lowest price charged in peer developed economies. Instead, biotech rose, large-cap pharma held firm, and the selling concentrated in the names the order might actually threaten: pharmacy benefit managers.

Something in the framing of the news cycle has been pointed at the wrong target.

The executive order, as read from the signing text on Monday, claims "prescription drug and pharmaceutical prices will be reduced almost immediately by 30 to 80%. They will rise throughout the world." That is the line the cable coverage has been running. The line misses, by a wide margin, what the most interesting feature of the EO actually does.

The math the cable coverage skips

The most cited comparison in the build-up to the order was KFF data reported via the Wall Street Journal: a 30-day supply of the diabetes drug Jardiance carries a $611 list price in the United States, $70 in Switzerland, and $35 in Japan. The implication is straightforward — Americans are paying ten to twenty times what their European peers pay for the same molecule, and a Most Favored Nation rule would collapse the gap.

That framing assumes the $611 is what anyone actually pays. TJ Parker, the former PillPack founder turned Matrix Partners investor who has spent a decade inside drug pricing mechanics, pointed out the gap between list and net on the same broadcast. The Ozempic $1,000 list price, he noted, masks a net price closer to $250 once rebates are factored. That is a $750 spread between sticker and reality — a spread captured by pharmacy benefit managers, insurers, and self-funded employer plans rather than by the manufacturer.

If the EO's operative clause forces US list prices to converge with international reference prices, but does not touch the rebate architecture, then net prices stay roughly where they are. Manufacturers' revenue is intact. The PBMs, however, lose the spread that sits between the two numbers.

The rebate backdoor

Parker's read on the Monday broadcast was that the EO's most consequential feature is precisely this mechanism. "If the real punchline here is that effectively this is a backdoor way to get rid of rebates, it's actually not that big of a deal for pharma — they're still getting their net economics, it's just that for the middleman," he said.

The political coalition behind the order, in other words, may have arrived at a more elegant target than European price controls. The headline-grabbing number — the gap between $611 in the US and $35 in Japan — does the rhetorical work. The structural work happens downstream, in the rebate contracts between manufacturers and the three PBMs that administer roughly 80% of US prescription claims.

That would explain the price action. Pharma held because its net economics were not the target. PBMs sold off because the rebate spread — the single largest line item in their P&L — became the target. The 4% biotech rally is consistent with a market that has concluded the EO is less a price-control event than a rebate reform event.

The 10% problem

The economic case against Most Favored Nation as a spending-cutter is older than the current debate. Kremt, an accountant and author who has modeled the 1991 MFN precedent, walked through the numbers on Monday. A Most Favored Consumer model implemented in the early 1990s produced no price change for patent-protected drugs, no change for generics, and roughly a 4% price increase for drugs facing generic competition. The mechanism was uniform pricing: as international prices rose to meet the US benchmark, manufacturers had less incentive to compete on the marginal molecule about to lose exclusivity.

The forward-looking model is harsher for the policy's advocates. Kremt's projection: only about a 10% reduction in US drug spending, paired with a roughly 90% increase in Canadian prices as manufacturers dynamically rebalanced across markets. A 10% reduction in a $600 billion annual drug bill is real money — somewhere in the $60 billion neighborhood — but it is not the 30-to-80% the executive order is promising. And a 90% increase in Canadian prices is not a side effect; it is a foreign policy problem.

Parker's caveat: "I could probably be convinced that a global most favored nation is a reasonable approach. The problem is even the federal government doesn't always know the actual net price of these drugs today." If the reference price is built on list, the savings are smaller than the rhetoric. If the reference price is built on net, the policy needs an apparatus the federal government does not currently possess.

The R&D question that nobody on the Monday broadcast answered

The structural worry is not the price tag on next year's formulary. It is the cost of capital inside the biotech industry over the next decade. Tess Cameron of RA Capital, the largest dedicated biotech investor, has been making this case publicly for two years. The probability-adjusted cost of bringing a drug to market now exceeds $2.5 billion, she noted on the broadcast. The Inflation Reduction Act's price-control thresholds — 9 years for small molecules, 13 for biologics — already compress the period of monopoly pricing manufacturers have to recoup that investment.

Kremt's framing was blunt: "We are paying way too much for drug development. We are paying out the nose for something that is not nearly as efficient as it could be." He added that pharma R&D internal rates of return are already below the average cost of capital. Layering a Most Favored Nation rule on top of an IRA regime on top of a generic-pricing structure that already produces a 4% increase under MFN models puts the industry's IRR problem into territory where capital allocators start choosing other things to do with their money.

The second-order effect is geographic. China reformed its clinical trial system in 2016 to allow nationwide recruitment, producing more trials and larger sample sizes than the US system currently runs. "China's actually beating the hell out of us because of some simple reforms that the FDA could actually implement right now," Kremt said. If US capital reallocates away from domestic biotech R&D, and Chinese trial infrastructure is faster and cheaper, the long-run question is where the next generation of medicines is actually invented.

The counter-model that nobody is talking about

There is a working alternative to Most Favored Nation that is sitting in plain sight. Louisiana's "Netflix model" for the hepatitis C drug Epclusa — a flat annual fee for unlimited supply — cut the state's hepatitis death rate by roughly one-sixth in about a year, per Kremt's read of the data. National scaling could solve the access problem on high-price drugs without the cross-border arbitrage that MFN invites.

The reason it is not on the table is that it requires the federal government to negotiate as a single buyer for a defined population — which is, in practice, what the VA already does and what Medicaid does for a subset of drugs. The political coalition that wants to attack PBM rebates is not the same coalition that wants to expand the federal government's role as a pharmaceutical purchaser. The two ideas solve overlapping problems but pull in opposite directions on the question of state capacity.

What Monday's tape is actually telling you

The 4% biotech rally and the PBM sell-off are consistent with a market that has read the executive order more carefully than the cable coverage. The order's headline number — 30 to 80% price reductions, paid for by foreign price increases — is the rhetoric. The order's structural target is the rebate spread between list and net. If that read is right, the policy is less about European price controls and more about dismantling the $750-per-script spread that PBMs, insurers, and self-funded employer plans currently extract.

That is a smaller, more technical, and more achievable policy than the one Trump described on Monday. It is also a policy that will produce loud opposition from a smaller, more concentrated set of incumbents. The market priced that opposition on the first trading day. The political fight will play out over the rest of the year.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://www.youtube.com/watch?v=1O6wn7af-1o